Sangamo Therapeutics (SGMO) Return on Invested Capital (2016 - 2025)
Sangamo Therapeutics has reported Return on Invested Capital over the past 9 years, most recently at 30.08% for Q4 2025.
- Quarterly results put Return on Invested Capital at 30.08% for Q4 2025, up 3343.0% from a year ago — trailing twelve months through Dec 2025 was 30.08% (up 3343.0% YoY), and the annual figure for FY2025 was 28.39%, down 2642.0%.
- Return on Invested Capital for Q4 2025 was 30.08% at Sangamo Therapeutics, up from 8.4% in the prior quarter.
- Over the last five years, Return on Invested Capital for SGMO hit a ceiling of 30.08% in Q4 2025 and a floor of 8.4% in Q3 2025.
- Median Return on Invested Capital over the past 5 years was 0.7% (2022), compared with a mean of 0.87%.
- Biggest five-year swings in Return on Invested Capital: plummeted -569bps in 2024 and later skyrocketed 3343bps in 2025.
- Sangamo Therapeutics' Return on Invested Capital stood at 0.47% in 2021, then crashed by -42bps to 0.67% in 2022, then plummeted by -269bps to 2.47% in 2023, then crashed by -36bps to 3.35% in 2024, then skyrocketed by 997bps to 30.08% in 2025.
- The last three reported values for Return on Invested Capital were 30.08% (Q4 2025), 8.4% (Q3 2025), and 5.11% (Q2 2025) per Business Quant data.